Zoliflodacin

佐氟达星

Report date: 2026/01/30 17:57:01
NMEFirst In ClassQIDP

Base Information

Drug NameZoliflodacin
Drug Alias NameZoliflodacina唑利氟达星ZoliflodacinumZoliflodacineNuzolvence +[8] 
ClassificationSmall molecules > Heterocyclic drugs > Antibiotics
Mechanisms of ActionBacterial DNA gyrase inhibitorsTopoisomerase IV inhibitors
TargetsBacterial DNA gyraseTopoisomerase IV
Therapy Area/IndicationsGonorrhea
Global Approved IndicationsGonorrhea
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2025/12/12
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesEntasis Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesEntasis TherapeuticsInnoviva Specialty Therapeutics IncEntasis Therapeutics Holdings Inc
Inactive CompaniesGlobal Antibiotic Research and Development Partnership FoundationAstrazeneca PlcNational Institute Of Allergy And Infectious Diseases (Niaid)
Active IndicationsGonorrhea
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG